Stephanie Reed
Director, Early Stage Formulation, Biopharmaceutical Development
Bio:
In her role at AstraZeneca, Dr. Stephanie Reed contributes to biopharmaceutical formulation drug product development across the pipeline, leading scientific teams and advanced strategic initiatives. Of particular interest are technologies to enable high-dose or complex subcutaneous delivery, encompassing formulation, device, and in silico/in vitro tools that predict protein interactions, bioavailability, and immunogenicity.
Her career spans parenteral, intraocular, and oral administered drug products, drug delivery using novel formulation and device approaches, long-acting implants and injectables, gastroretentive dosage forms, polymers and novel excipients, additive manufacturing, stem cell tissue engineering, and biomaterial biocompatibility.
With 13 years of industry experience across pharma and med device, 11 years of academic research, 17 issued patents, 12 regulatory approvals, and 25+ technology partnerships, Stephanie is keen on mapping strategic pathways to translate innovations for investment and commercialization.
Stephanie earned her PhD and MS in biomedical engineering from UCLA and BS in mechanical engineering from MIT.